Skip to main content
. 2006 Apr 5;26(14):3855–3863. doi: 10.1523/JNEUROSCI.4957-05.2006

Figure 1.

Figure 1.

Behavioral studies. A, Effect of pretreatment (subcutaneous) with the dopamine D1 receptor antagonist SCH 23390 (SCH; doses in mg/kg) on the enhancement of startle by CRF (1 μg, i.c.v.). There was a significant dose-dependent reduction in CRF-enhanced startle by SCH 23390 (0.05 and 0.1 mg/kg) during peak CRF effects on startle; data are collapsed across blocks of 50 min for statistical comparisons. B, Effect of SCH 23390 on baseline startle responding. Baseline startle was not significantly different from vehicle controls (VEH-VEH group) at any dose of SCH 23390 (SCH) except for the high dose (0.5 mg/kg) during the first 50 min block of time. C, D, Full time course data are expressed as the percentage difference from the VEH-VEH group for the effect of SCH 23390 (SCH) on CRF-enhanced startle (C) and baseline startle (D). *p < 0.05, **p < 0.005, ***p < 0.0005 compared with VEH-VEH group; †p < 0.05, ††p < 0.005 compared with VEH-CRF group.